Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Experimental Therapeutics

Evaluation of Double- and Triple-Antibiotic Combinations for VIM- and NDM-Producing Klebsiella pneumoniae by In Vitro Time-Kill Experiments

T. Tängdén, R. A. Hickman, P. Forsberg, P. Lagerbäck, C. G. Giske, O. Cars
T. Tängdén
aDepartment of Medical Sciences, Section of Infectious Diseases, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. A. Hickman
aDepartment of Medical Sciences, Section of Infectious Diseases, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Forsberg
aDepartment of Medical Sciences, Section of Infectious Diseases, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Lagerbäck
aDepartment of Medical Sciences, Section of Infectious Diseases, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. G. Giske
bClinical Microbiology, MTC, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O. Cars
aDepartment of Medical Sciences, Section of Infectious Diseases, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00741-13
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Combination therapy is recommended for infections with carbapenemase-producing Klebsiella pneumoniae. However, limited data exist on which antibiotic combinations are the most effective. The aim of this study was to find effective antibiotic combinations against metallo-beta-lactamase-producing K. pneumoniae (MBL-KP). Two VIM- and two NDM-producing K. pneumoniae strains, all susceptible to colistin, were exposed to antibiotics at clinically relevant static concentrations during 24-h time-kill experiments. Double- and triple-antibiotic combinations of aztreonam, ciprofloxacin, colistin, daptomycin, fosfomycin, meropenem, rifampin, telavancin, tigecycline, and vancomycin were used. Synergy was defined as a ≥2 log10 decrease in CFU/ml between the combination and its most active drug after 24 h, and bactericidal effect was defined as a ≥3 log10 decrease in CFU/ml after 24 h compared with the starting inoculum. Synergistic or bactericidal activity was demonstrated for aztreonam, fosfomycin, meropenem, and rifampin in double-antibiotic combinations with colistin and also for aztreonam, fosfomycin, and rifampin in triple-antibiotic combinations with meropenem and colistin. Overall, the combination of rifampin-meropenem-colistin was the most effective regimen, demonstrating synergistic and bactericidal effects against all four strains. Meropenem-colistin, meropenem-fosfomycin, and tigecycline-colistin combinations were not bactericidal against the strains used. The findings of this and other studies indicate that there is great potential of antibiotic combinations against carbapenemase-producing K. pneumoniae. However, our results deviate to some extent from those of previous studies, which might be because most studies to date have included KPC-producing rather than MBL-producing strains. More studies addressing MBL-KP are needed.

INTRODUCTION

Carbapenem resistance in Enterobacteriaceae has increased globally during the past decade, particularly in Klebsiella pneumoniae, and is typically caused by carbapenemase production. However, there have been marked geographic differences in the epidemiology of carbapenemases. Serine KPC-type carbapenemases are predominant in the United States and frequently reported in Southern Europe (1). OXA-48, which was first detected in Turkey, has increased particularly in Europe, the Mediterranean, and North Africa (1, 2). VIM-type metallo-beta-lactamases (MBLs) are endemic in some European countries, whereas IMP-type MBLs are predominant in Asia (3–5). In recent years, Enterobacteriaceae producing NDM-1-type MBLs have disseminated rapidly on the Indian subcontinent (1).

Carbapenemase-producing K. pneumoniae strains are of great clinical concern because of frequent coresistance to multiple antibiotic classes (6, 7). Clinical studies have concluded that combination antibiotic therapy is associated with a better outcome than monotherapy for the treatment of severe infections with these strains, even if the isolated bacteria are susceptible in vitro to the individual drugs (8–10). However, inadequate data exist on which antibiotic combinations are the most effective. To date, recommendations are based on a few retrospective clinical studies and in vitro studies with time-kill or checkerboard methods. Clinical studies have reported favorable outcomes for patients treated with combinations of colistin and a carbapenem, tigecycline, fosfomycin, or an aminoglycoside (10–12). Retrospective analyses have supported the use of combinations including a carbapenem for infections with KPC-producing K. pneumoniae when the carbapenem MIC of the causative bacteria is ≤4 mg/liter (11). These combinations have been recommended and used in clinical practice (13). Double- and triple-antibiotic combinations that include colistin, a carbapenem, rifampin, tigecycline, and fosfomycin have proven effective in vitro and been proposed for clinical use (14–18).

Notably, most studies have addressed KPC-producing K. pneumoniae, and antibiotic combinations considered effective in these studies have not been readily evaluated against MBL-producing strains. Because MBL-producing K. pneumoniae are increasing globally, there is an urgent need to evaluate antibiotic regimens for the treatment of infections caused by these strains. In the absence of clinical studies, which are difficult to perform, in vitro studies may give some insight into this issue. The aim of the present study was to find antibiotic combinations with synergistic and bactericidal activity against VIM- and NDM-producing K. pneumoniae isolates in vitro.

MATERIALS AND METHODS

Bacteria and media.Mueller-Hinton II broth (MHBII) and Mueller-Hinton II agar plates were used for all experiments (Becton, Dickinson & Co., Sparks, MD, USA). Clinical isolates of K. pneumoniae producing VIM-1 and NDM-1 carbapenemases were obtained from the Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden. The VIM-1-producing K. pneumoniae (VIM-KP) strains T14789 and ÖN-2211 were originally isolated in Scandinavia but derived from patients recently transferred from Greek hospitals, while the NDM-1-producing K. pneumoniae (NDM-KP) isolates IR8 and IR62E originated from Chennai, India. All strains have been described in previous publications (7, 19).

Antibiotic susceptibility testing.MICs were determined in triplicate with the Etest method according to the manufacturer's instructions (bioMérieux, Marcy l'Etoile, France).

Detection of coproduced beta-lactamases.The Check-MDR CT101 array (Check-Points, Wageningen, The Netherlands) was used as recommended by the manufacturer to identify the beta-lactamase genes of extended-spectrum beta-lactamases (ESBLs) and plasmid-mediated AmpCs (pAmpCs). Carbapenemase genes had been detected earlier (7, 19).

Antibiotic concentrations.Antibiotic concentrations used during time-kill experiments represent mean steady-state concentrations of non-protein-bound drug in humans calculated from literature data (based on the area under the antibiotic concentration-time curve in serum or plasma over 24 h divided by 24 h [AUC0–24/24 h]). For rifampin, the mean concentration [(Cmax + Cmin)/2] was used instead due to a lack of other data. The following concentrations were used: 17 mg/liter for aztreonam (20), 1.0 mg/liter for ciprofloxacin (21), 4.0 mg/liter for colistin (22), 1.7 mg/liter for daptomycin (23), 83 mg/liter for fosfomycin (24), 6.8 mg/liter for meropenem (25), 1.7 mg/liter for rifampin (26), 3.3 mg/liter for telavancin (27), 0.1 mg/liter for tigecycline (28), and 9.1 mg/liter for vancomycin (29).

Time-kill experiments.A single bacterial colony was added to 2 ml MHBII and grown for 15 to 18 h in a 37°C rocking water bath (150 rpm). A total of 20 μl of the overnight culture was added to 2 ml of prewarmed MHBII, further incubated for 1.5 h, and then inoculated in prewarmed MHBII to obtain a starting inoculum of approximately 5 × 106 CFU/ml. Antibiotics were added to the concentrations described above. Samples were taken at 0, 1, 2, 4, 6, and 24 h, serially diluted, spread on plates, and incubated at 37°C. Bacterial colonies were counted after 24 h.

Experimental design.The VIM-KP strains were exposed to colistin alone and aztreonam, fosfomycin, meropenem, rifampin, ciprofloxacin, tigecycline, daptomycin, telavancin, and vancomycin alone and in combination with colistin in 24-h time-kill experiments. Based on the synergistic and bactericidal effects detected in these experiments and results from previously published studies, we decided to perform further experiments with double- and triple-antibiotic combinations of aztreonam, fosfomycin, meropenem, rifampin, and colistin. Antibiotics that demonstrated synergistic or bactericidal effects when used in combination with other drugs against the VIM-KP strains were selected for further experiments against the NDM-KP strains. Experiments were performed at least in triplicate for the VIM-KP strains and at least in duplicate for the NDM-KP strains. In total, we performed more than 200 time-kill experiments with 24 antibiotic regimens, including 14 antibiotic combinations.

Analysis of time-kill experiments.The lower limit of bacterial detection was 1.0 log10 CFU/ml. Bacterial concentrations of <1.0 log10 CFU/ml were counted as 1.0 log10 CFU/ml. Synergy was defined as a ≥2 log10 decrease in CFU/ml between the combination and its most active constituent after 24 h. Bactericidal effect was defined as a ≥3 log10 decrease in CFU/ml after 24 h compared with the starting inoculum.

RESULTS

All strains were susceptible to colistin according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (www.eucast.org), whereas susceptibilities to the other antibiotics varied substantially (Table 1). The following genes encoding ESBLs and pAmpCs were detected: VIM-KP T14789, blaCMY-I and blaMOX; VIM-KP ÖN-2211, blaCTX-M-1 group; NDM-KP IR8, blaCTX-M-1 group; NDM-KP IR62E, blaCMY-II, blaDHA, and blaCTX-M-1 group.

View this table:
  • View inline
  • View popup
TABLE 1

Antibiotic susceptibilities of VIM- and NDM-producing K. pneumoniae strains expressed as MIC values and classification according to the clinical breakpoints defined by EUCASTa

Colistin, alone and in any combination with other antibiotics, was associated with a >3 log10 decrease in CFU/ml during the first hour of the experiments. However, considerable regrowth occurred for most colistin combinations and during experiments with colistin alone. Synergistic and bactericidal effects after 24 h were found for combinations that included aztreonam, fosfomycin, meropenem, rifampin, and colistin (Tables 2, 3, 4, 5, and 6; see also Fig. S1 to S4 in the supplemental material).

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 2

Compiled results from time-kill experiments with combinations that include meropenem, colistin, aztreonam, fosfomycin, and rifampin against VIM- and NDM-producing K. pneumoniae

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 3

Summary of mean bacterial concentrations at 0, 1, and 24 h during time-kill experiments performed against VIM-producing K. pneumoniae strain VIM-KP T14789a

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 4

Summary of mean bacterial concentrations at 0, 1, and 24 h during time-kill experiments performed against VIM-producing K. pneumoniae strain VIM-KP ÖN-2211a

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 5

Summary of mean bacterial concentrations at 0, 1, and 24 h during time-kill experiments performed against NDM-producing K. pneumoniae strain NDM-KP IR8a

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 6

Summary of mean bacterial concentrations at 0, 1, and 24 h during time-kill experiments performed against NDM-producing K. pneumoniae strain NDM-KP IR62Ea

Aztreonam-colistin and aztreonam-meropenem-colistin were bactericidal against the VIM-KP strains, both of which displayed intermediate susceptibility to aztreonam. These combinations resulted in more rapid killing than aztreonam alone and less regrowth than colistin alone and proved a synergistic effect against VIM-KP ÖN-2211 (Tables 3 and 4; see also Fig. S1 and S2a in the supplemental material). Against the NDM-KP strains, aztreonam-meropenem-colistin demonstrated a synergistic effect despite high-level resistance to aztreonam and reduced susceptibility to meropenem. However, the effect was not bactericidal (Tables 5 and 6; see also Fig. S3 and S4a in the supplemental material). Meropenem-colistin had a synergistic effect against NDM-KP IR62E, but the combination was not bactericidal and showed no synergistic or bactericidal effects against the other strains (Tables 3 to 6; see also Fig. S1 to S4d in the supplemental material).

The combination fosfomycin-colistin demonstrated synergy and a bactericidal effect against one of the VIM-KP strains and both NDM-KP strains despite that the latter strains were resistant to fosfomycin (Tables 3 to 6; see also Fig. S1 to S4b in the supplemental material). Fosfomycin-meropenem-colistin showed a synergistic effect against all strains and a bactericidal effect against three of the four strains.

Rifampin-colistin demonstrated synergy and a >2.5 log10 decrease in CFU/ml after 24 h compared with the starting inoculum against both NDM strains (Tables 5 and 6; see also Fig. S3 and S4c in the supplemental material). The triple-antibiotic combination rifampin-meropenem-colistin resulted in synergistic and bactericidal effects against all strains despite high MICs for rifampin in all strains and despite that two of the strains were highly resistant to meropenem alone (Tables 3 to 6; see also Fig. S1 to S4c in the supplemental material).

The antibacterial activities of ciprofloxacin, tigecycline, daptomycin, telavancin, and vancomycin alone and in combination with colistin against the VIM-KP strains were evaluated in time-kill experiments performed in triplicate (Tables 3 and 4; see also Fig. S1 and S2e in the supplemental material). However, no synergistic or bactericidal activity was detected with these antibiotic regimens, and thus they were not further investigated against the NDM-KP strains.

DISCUSSION

In this study, we have used 14 antibiotic combinations against four MBL-producing K. pneumoniae strains and found synergistic or bactericidal activity for seven of these combinations in time-kill experiments at clinically relevant static antibiotic concentrations.

Our results are in part consistent with those of previous studies. Overall, the combination of rifampin-meropenem-colistin was the most effective regimen, demonstrating synergistic and bactericidal effects against all four strains. A similar triple-antibiotic combination of rifampin-doripenem-colistin has been shown to have a bactericidal effect against KPC-producing K. pneumoniae strains in time-kill experiments at antibiotic concentrations of 0.25× MIC (17). Rifampin-colistin was synergistic against both NDM-KP strains in our study and has been effective against the majority of KPC-producing K. pneumoniae isolates in previous time-kill and checkerboard studies (14, 30). Fosfomycin-colistin, which showed synergistic and bactericidal effects against 3 of 4 strains in our study, has previously demonstrated synergy against 2 of 4 NDM-producing Klebsiella spp. in a study with the checkerboard method (15).

Some antibiotic combinations that have been effective against carbapenemase-producing K. pneumoniae in previous studies and recommended for clinical use showed no synergistic or bactericidal effects in our experiments. For example, meropenem-colistin was not bactericidal against any of the strains despite susceptibility to colistin in all strains and susceptibility or intermediate susceptibility to meropenem in two of the strains. The combination of tigecycline-colistin has demonstrated a synergistic and bactericidal effect against KPC-producing K. pneumoniae in previous studies with checkerboard and time-kill methods but was not effective against the VIM-KP isolates used in this study (14, 18). Further, meropenem-fosfomycin, which demonstrated synergistic and bactericidal effects against the majority of KPC-producing K. pneumoniae isolates in a previous time-kill study, was not effective in our experiments (16).

The combination of aztreonam-meropenem-colistin showed a synergistic or bactericidal effect against all strains, despite that the NDM-KP isolates were highly resistant to aztreonam and nonsusceptible to meropenem. One possible explanation for this finding is that aztreonam acts as a competitive MBL inhibitor and meropenem as a competitive inhibitor for other coproduced beta-lactamases (such as ESBLs or AmpCs) that hydrolyze aztreonam but not meropenem. Such competitive inhibitory activities have previously been demonstrated for aztreonam against MBLs and for meropenem against class A, C, and D beta-lactamases (31). The combined inhibitory activities of aztreonam and meropenem were not sufficient to achieve synergy against the MBL-producing K. pneumoniae strains used in this study. However, the addition of colistin resulted in synergistic activity, probably because of increased permeability leading to higher concentrations of aztreonam and meropenem in the periplasmic space with this combination (32).

In summary, we have found several double- and triple-antibiotic combinations of aztreonam, fosfomycin, meropenem, rifampin, and colistin with synergistic and bactericidal effects against MBL-producing K. pneumoniae. Bacterial regrowth at 24 h occurred for most combinations, but the clinical relevance is uncertain, because the experiments were performed at static antibiotic concentrations in vitro, where the effects of the immune system are not taken into account. Our results suggest that rifampin-meropenem-colistin is effective for infections with these strains and that aztreonam-colistin with or without meropenem might be a therapeutic option even when the causative bacteria are not susceptible to aztreonam. More studies are required to confirm the efficacy and evaluate the clinical use of these combinations. Yet our results are encouraging and indicate that there is an antibacterial potential of antibiotic combinations against MBL-producing K. pneumoniae. Effective combinations might include antibiotics to which the bacteria are resistant as well as drugs not usually considered therapeutic options for Gram-negative bacteria. Our results are somewhat inconsistent with those previously reported for carbapenemase-producing K. pneumoniae, which might be explained in part by the fact that most studies to date have addressed KPC-producing rather than MBL-producing strains.

Because clinical studies are not easily performed with patients infected with these bacteria, therapeutic decisions will sometimes depend on the results from in vitro studies. Therefore, we believe that there is an urgent need for more time-kill studies aimed at finding effective antibiotic combinations for the treatment of MBL-producing K. pneumoniae.

ACKNOWLEDGMENTS

This work was supported by VINNOVA and the Swedish Foundation for Strategic Research.

We thank Charlotte Annerstedt for excellent laboratory assistance.

FOOTNOTES

    • Received 23 April 2013.
    • Returned for modification 18 August 2013.
    • Accepted 29 December 2013.
    • Accepted manuscript posted online 6 January 2014.
  • Supplemental material for this article may be found at http://dx.doi.org/10.1128/AAC.00741-13.

  • Copyright © 2014, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Nordmann P,
    2. Naas T,
    3. Poirel L
    . 2007. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 17:1791–1798. doi:10.3201/eid1710.110655.
    OpenUrlCrossRef
  2. 2.↵
    1. Cantón R,
    2. Akóva M,
    3. Carmeli Y,
    4. Giske CG,
    5. Glupczynski Y,
    6. Gniadkowski M,
    7. Livermore DM,
    8. Miriagou V,
    9. Naas T,
    10. Rossolini GM,
    11. Samuelsen Ø,
    12. Seifert H,
    13. Woodford N,
    14. Nordmann P
    . 2012. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 18:413–431. doi:10.1111/j.1469-0691.2012.03821.x.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Souli M,
    2. Galani I,
    3. Antoniadou A,
    4. Papadomichelakis E,
    5. Poulakou G,
    6. Panagea T,
    7. Vourli S,
    8. Zerva L,
    9. Armaganidis A,
    10. Kanellakopoulou K,
    11. Giamarellou H
    . 2010. An outbreak of infection due to beta-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes. Clin. Infect. Dis. 50:364–373. doi:10.1086/649865.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Walsh TR
    . 2008. Clinically significant carbapenemases: an update. Curr. Opin. Infect. Dis. 21:367–371. doi:10.1097/QCO.0b013e328303670b.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Cagnacci S,
    2. Gualco L,
    3. Roveta S,
    4. Mannelli S,
    5. Borgianni L,
    6. Docquier JD,
    7. Dodi F,
    8. Centanaro M,
    9. Debbia E,
    10. Marchese A,
    11. Rossolini GM
    . 2008. Bloodstream infections caused by multidrug-resistant Klebsiella pneumoniae producing the carbapenem-hydrolysing VIM-1 metallo-beta-lactamase: first Italian outbreak. J. Antimicrob. Chemother. 61:296–300. doi:10.1093/jac/dkm471.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Kumarasamy KK,
    2. Toleman MA,
    3. Walsh TR,
    4. Bagaria J,
    5. Butt F,
    6. Balakrishnan R,
    7. Chaudhary U,
    8. Doumith M,
    9. Giske CG,
    10. Irfan S,
    11. Krishnan P,
    12. Kumar AV,
    13. Maharjan S,
    14. Mushtaq S,
    15. Noorie T,
    16. Paterson DL,
    17. Pearson A,
    18. Perry C,
    19. Pike R,
    20. Rao B,
    21. Ray U,
    22. Sarma JB,
    23. Sharma M,
    24. Sheridan E,
    25. Thirunarayan MA,
    26. Turton J,
    27. Upadhyay S,
    28. Warner M,
    29. Welfare W,
    30. Livermore DM,
    31. Woodford N
    . 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10:597–602. doi:10.1016/S1473-3099(10)70143-2.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Samuelsen Ø,
    2. Toleman MA,
    3. Hasseltvedt V,
    4. Fuursted K,
    5. Leegaard TM,
    6. Walsh TR,
    7. Sundsfjord A,
    8. Giske CG
    . 2011. Molecular characterization of VIM-producing Klebsiella pneumoniae from Scandinavia reveals genetic relatedness with international clonal complexes encoding transferable multidrug resistance. Clin. Microbiol. Infect. 17:1811–1816. doi:10.1111/j.1469-0691.2011.03532.x.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Zarkotou O,
    2. Pournaras S,
    3. Tselioti P,
    4. Dragoumanos V,
    5. Pitiriga V,
    6. Ranellou K,
    7. Prekates A,
    8. Themeli-Digalaki K,
    9. Tsakris A
    . 2011. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin. Microbiol. Infect. 17:1798–1803. doi:10.1111/j.1469-0691.2011.03514.x.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Qureshi ZA,
    2. Paterson DL,
    3. Potoski BA,
    4. Kilayko MC,
    5. Sandovsky G,
    6. Sordillo E,
    7. Polsky B,
    8. Adams-Haduch JM,
    9. Doi Y
    . 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob. Agents Chemother. 56:2108-2113. doi:10.1128/AAC.06268-11.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Hirsch EB,
    2. Tam VH
    . 2010. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J. Antimicrob. Chemother. 65:1119–1125. doi:10.1093/jac/dkq108.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Daikos GL,
    2. Markogiannakis A
    . 2011. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin. Microbiol. Infect. 17:1135–1141. doi:10.1111/j.1469-0691.2011.03553.x.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Michalopoulos A,
    2. Virtzili S,
    3. Rafailidis P,
    4. Chalevelakis G,
    5. Damala M,
    6. Falagas ME
    . 2010. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin. Microbiol. Infect. 16:184–186. doi:10.1111/j.1469-0691.2009.02921.x.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Miyakis S,
    2. Pefanis A,
    3. Tsakris A
    . 2011. The challenges of antimicrobial drug resistance in Greece. Clin. Infect. Dis. 53:177–184. doi:10.1093/cid/cir323.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Elemam A,
    2. Rahimian J,
    3. Doymaz M
    . 2010. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J. Clin. Microbiol. 48:3558–3562. doi:10.1128/JCM.01106-10.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Bercot B,
    2. Poirel L,
    3. Dortet L,
    4. Nordmann P
    . 2011. In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae. J. Antimicrob. Chemother. 66:2295–2297. doi:10.1093/jac/dkr296.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Souli M,
    2. Galani I,
    3. Boukovalas S,
    4. Gourgoulis MG,
    5. Chryssouli Z,
    6. Kanellakopoulou K,
    7. Panagea T,
    8. Giamarellou H
    . 2011. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob. Agents Chemother. 55:2395–2397. doi:10.1128/AAC.01086-10.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Urban C,
    2. Mariano N,
    3. Rahal JJ
    . 2010. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob. Agents Chemother. 54:2732–2734. doi:10.1128/AAC.01768-09.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Pournaras S,
    2. Vrioni G,
    3. Neou E,
    4. Dendrinos J,
    5. Dimitroulia E,
    6. Poulou A,
    7. Tsakris A
    . 2011. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int. J. Antimicrob. Agents 37:244–247. doi:10.1016/j.ijantimicag.2010.10.031.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Giske CG,
    2. Fröding I,
    3. Hasan CM,
    4. Turlej-Rogacka A,
    5. Toleman M,
    6. Livermore D,
    7. Woodford N,
    8. Walsh TR
    . 2012. Diverse sequence types of Klebsiella pneumoniae contribute to the dissemination of blaNDM-1 in India, Sweden, and the United Kingdom. 56:2735–2738. doi:10.1128/AAC.06142-11.
    OpenUrlCrossRef
  20. 20.↵
    1. Meyers BR,
    2. Wilkinson P,
    3. Mendelson MH,
    4. Bournazos C,
    5. Tejero C,
    6. Hirschman SZ
    . 1993. Pharmacokinetics of aztreonam in healthy elderly and young adult volunteers. J. Clin. Pharmacol. 33:470–474. doi:10.1002/j.1552-4604.1993.tb04690.x.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Lettieri JT,
    2. Rogge MC,
    3. Kaiser L,
    4. Echols RM,
    5. Heller AH
    . 1992. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob. Agents Chemother. 36:993–996. doi:10.1128/AAC.36.5.993.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Garonzik SM,
    2. Li J,
    3. Thamlikitkul V,
    4. Paterson DL,
    5. Shoham S,
    6. Jacob J,
    7. Silveira FP,
    8. Forrest A,
    9. Nation RL
    . 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55:3284–3294. doi:10.1128/AAC.01733-10.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Dvorchik BH,
    2. Brazier D,
    3. DeBruin MF,
    4. Arbeit RD
    . 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318–1323. doi:10.1128/AAC.47.4.1318-1323.2003.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Matzi V,
    2. Lindenmann J,
    3. Porubsky C,
    4. Kugler SA,
    5. Maier A,
    6. Dittrich P,
    7. Smolle-Jüttner FM,
    8. Joukhadar C
    . 2010. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J. Antimicrob. Chemother. 65:995–998. doi:10.1093/jac/dkq070.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Conte JE Jr,
    2. Golden JA,
    3. Kelley MG,
    4. Zurlinden E
    . 2005. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int. J. Antimicrob. Agents. 26:449–456. doi:10.1016/j.ijantimicag.2005.08.015.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    Pfizer. 2011. Rifampin: package insert. Pfizer Labs, New York, NY.
  27. 27.↵
    Theravance. 2009. Vibativ: package insert. Theravance, San Francisco, CA.
  28. 28.↵
    1. Meagher AK,
    2. Ambrose PG,
    3. Grasela TH,
    4. Ellis-Grosse EJ
    . 2005. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn. Microbiol. Infect. Dis. 52:165–171. doi:10.1016/j.diagmicrobio.2005.05.006.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. James JK,
    2. Palmer SM,
    3. Levine DP,
    4. Rybak MJ
    . 1996. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented Gram-positive infections. Antimicrob. Agents Chemother. 40:696–700.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Bratu S,
    2. Tolaney P,
    3. Karumudi U,
    4. Quale J,
    5. Mooty M,
    6. Nichani S,
    7. Landman D
    . 2005. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56:128–132. doi:10.1093/jac/dki175.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Drawz SM,
    2. Bonomo RA
    . 2010. Three decades of beta-lactamase inhibitors. Clin. Microbiol. Rev. 23:160–201. doi:10.1128/CMR.00037-09.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Rahal JJ
    . 2009. Antimicrobial resistance among and therapeutic options against Gram-negative pathogens. Clin. Infect. Dis. 49(Suppl):S4–S10. doi:10.1086/599810.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Evaluation of Double- and Triple-Antibiotic Combinations for VIM- and NDM-Producing Klebsiella pneumoniae by In Vitro Time-Kill Experiments
T. Tängdén, R. A. Hickman, P. Forsberg, P. Lagerbäck, C. G. Giske, O. Cars
Antimicrobial Agents and Chemotherapy Feb 2014, 58 (3) 1757-1762; DOI: 10.1128/AAC.00741-13

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of Double- and Triple-Antibiotic Combinations for VIM- and NDM-Producing Klebsiella pneumoniae by In Vitro Time-Kill Experiments
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evaluation of Double- and Triple-Antibiotic Combinations for VIM- and NDM-Producing Klebsiella pneumoniae by In Vitro Time-Kill Experiments
T. Tängdén, R. A. Hickman, P. Forsberg, P. Lagerbäck, C. G. Giske, O. Cars
Antimicrobial Agents and Chemotherapy Feb 2014, 58 (3) 1757-1762; DOI: 10.1128/AAC.00741-13
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596